Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

Exit

PublicNASDAQ:RXDX
Date3/2014
Raised$48M
Post IPO Valuation

General Information

Offices

San Diego, USA
11575 Sorrento Valley Road
Suite 200
San Diego, CA, 92121
USA

People

Vice President, Medicinal Chemistry
Vice President, Biology
Board of Directors
Board of Directors
Director of Bioinformatics
Chairman, CEO and Co-Founder
Chief Scientific Officer and SVP, Head of Research
CFO and VP, Corporate Development
Chief Medical Officer

Acquisitions

Funding

TOTAL $59.5M
FUNDING TOTAL $59.5M
Series B, 12/2012
City Hill Ventures
Colt Ventures
Silicon Valley Bank
$5.5M
Venture Round, 12/2013
$54M
DEBT TOTAL $11M
Debt, 2/2013
$1M
Debt, 1/2014
Silicon Valley Bank
$10M

Tags

Ignyta

Ignyta is a scientifically driven biotechnology company catalyzing personalized medicine in autoimmune diseases. Their goals are to revolutionize the quality of biomarkers and tests available to rheumatologists and patients to help them make better informed, more individualized treatment decisions; and to identify truly novel autoimmune disease targets for biopharmaceutical companies to enable the development of precise therapies for patients worldwide.

Recent Milestones

  • Stock
    Went public with stock symbol NASDAQ:RXDX. (3/14/14)
    Posted 3/14/14 at 6:02pm
  • Dollar
    Ignyta received $10M in Debt funding. (1/6/14)
    Posted 1/6/14 at 5:43am via socaltech.com
  • Dollar
    Ignyta received $54M in Venture Round funding. (12/3/13)
    Posted 11/14/13 at 7:40pm via biospace.com
  • Handshake
    Ignyta acquired Actagene Oncology. (5/20/13)
    Posted 5/20/13 at 9:23pm via bloomberg.com
  • Dollar
    Ignyta received $1M in Debt funding. (2/28/13)
    Posted 2/28/13 at 7:29pm via dowjones.com
  • Dollar
    Ignyta received $5.5M in Series B funding. (12/31/12)
    Posted 1/3/13 at 3:20am via prweb.com
  • Check
    Ignyta added Jonathan Lim as Chairman, CEO and Co-Founder.
    Posted 11/17/13 at 1:15am

Videos

Screenshots

Ignyta screenshot
Above: Ignyta
Uploaded: 1/3/13

Stock Price

Sources

  1. Ignyta Announces Acquisition of Actagene Oncology and Entry into Oncology Personalized Medicine (bloomberg.com) [edit]
  2. Ignyta Ends 2012 with Oversubscribed, Expanded Series B Financing (prweb.com) [edit]
  3. Ignyta Receives $1M Capital Term Loan From Silicon Valley Bank (pevc.dowjones.com) [edit]
  4. Ignyta Scores $54 Million To Catalyze Precision Medicine For Cancer Patients (biospace.com) [edit]
  5. Ignyta Gets $10M In Term Loan (socaltech.com) [edit]
Edit This Page
Last Edited 3/14/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize »

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy